The NIMML has established an extensible innovation pipeline for developing safer and more effective therapeutics for immune-mediated, infectious and chronic inflammatory diseases.

Lanthionine synthetase component C-like protein 2: a new drug target for inflammatory diseases and diabetes.

Translational research and efficacy of biologics in Crohn’s disease: a cautionary tale.

Systems modeling of molecular mechanisms controlling cytokine-driven CD4+ T cell differentiation and phenotype plasticity.

Enteroaggregative Escherichia coli strain in a novel weaned mouse model: exacerbation by malnutrition, biofilm as a virulence factor and treatment by nitazoxanide.

Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn’s disease.

Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein 2.

Dietary α-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-γ.

Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeutics.

The NIMML Institute is actively involved in economic development and job creation. We offer a diverse portfolio of patents and intellectual property and seek to establish key strategic alliances with pharma and biotech companies, which will help us to translate our new scientific breakthroughs from the laboratory bench to the global market.

Companies in the NIMML Institute Ecosystem:

BioTherapeutics, Inc. is an emerging biotech company that synergistically combines the power of advanced computational modeling with translational experimentation to accelerate the development of novel products for precision medicine and health. For more information, please visit www.biotherapeuticsinc.com.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company completed Phase 1 clinical testing in 2018 and initiated global Phase 2 clinical testing of BT-11 for ulcerative colitis (UC) in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which Landos anticipates will advance to Phase 1 clinical testing in 2020. For more information, please visit www.landosbiopharma.com.

Pervida, Inc. is an award-winning beverage company dedicated to creating and commercializing natural products with potent and proven health benefits. Pervida’s flagship product–Pervida Immune, supports the immune system using a patented, all-natural source of anti-inflammatories for a healthy life. For more information, please contact us at [email protected], follow us on social media: @PervidaHealth or visit www.pervida.com.